儿童肺炎旁胸腔积液/脓胸发病率趋势:PCV13引入后仅呈暂时下降
该研究基于德国Barmer法定健康保险约覆盖11%人口的次级医疗数据,分析2009至2018年≤18岁儿童肺炎旁胸腔积液/脓胸(PPE/PE)年发病率。十年总体发病率为18.17/10万,0-1岁最高(43.09/10万);发病率2009至2013年下降(2013年谷值15.36;95%CI:13.41-17.31),2013年后逐年上升,广义可加模型显示近乎U型曲线(p-non-linear=0.0017)。
要点
- 十年总体发病率18.17/10万,0-1岁组最高(43.09/10万)。
- 2013年为谷值(15.36;95%CI:13.41-17.31),此后逐年上升。
- 作者推测下降与血清型1近乎消失、上升与血清型3占比增加有关。
核心结论
- 儿童PPE/PE发病率呈非线性时间趋势:2009至2013年下降,2013年后至2018年上升。
- PCV13对PPE/PE总体发病率的影响仅为暂时性下降。
研究设计与样本
- 基于德国Barmer法定健康保险2009-2018年次级医疗数据的回顾性发病率分析。
- 数据覆盖约11%的德国人口,采用广义可加模型拟合年发病率时间趋势。
- 研究对象为≤18岁儿童,按0-1岁、2-5岁、6-18岁分组分析。
主要发现
- 十年观察期内≤18岁儿童PPE/PE总体发病率为18.17/10万。
- 0-1岁组发病率最高,为43.09/10万。
- 2-5岁组谷值为15.85(95%CI:11.27-20.43),6-18岁组为12.29(95%CI:10.23-14.36),均出现在2013年。
- 0-1岁组谷值出现在2014年,为32.66(95%CI:23.79-41.54)。
- GAM显示按日历年PPE/PE发病率与时间呈近乎U型曲线(p-non-linear=0.0017),模型确认2013年为谷值年。
关键数值与推荐
- 总体发病率18.17/10万;0-1岁43.09/10万。
- 2013年总体谷值15.36(95%CI:13.41-17.31)。
- 2-5岁谷值15.85(95%CI:11.27-20.43);6-18岁谷值12.29(95%CI:10.23-14.36)。
- 0-1岁谷值(2014年)32.66(95%CI:23.79-41.54)。
- GAM非线性检验p-non-linear=0.0017。
临床怎么用
- 提示PCV13免疫规划后儿童PPE/PE负担可能出现反弹,需持续监测发病率。
- 应结合血清型监测评估免疫策略效果,关注血清型3占比变化。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, emergence of a higher proportion of serotype 3 in children with parapneumonic pleural effusion/empyema (PPE/PE) were observed in Germany despite general immunization with 13-valent pneumococcal conjugate vaccine (PCV13) since 2009. The impact of PCV13 on the overall incidence of PPE/PE in children is unclear. METHODS: Annual incidence of PPE/PE in children were determined using secondary health care data for 2009-2018, provided by the Barmer statutory health insurer, serving about 11% of the German population. Temporal trends of the annual incidence were modelled applying generalized additive models. RESULTS: Overall incidence of PPE/PE in children ( ≤18 years) in the ten-year observation period was 18.17 per 100,000. The 0-1 year olds showed the highest incidence (43.09 per 100 000). PPE/PE incidence decreased from 2009 until 2013 (nadir 2013 was 15.36; 95% CI: 13.41-17.31). Since 2013, the data show an annual increase. The nadir of incidence for the 2-5 year olds (15.85; 95% CI: 11.27-20.43) and the 6-18 year olds (12.29; 95% CI: 10.23-14.36) was also in 2013, whereas for the 0-1 year olds it was found in 2014 (32.66; 95% CI: 23.79-41.54). The GAM across all age groups showed a nearly U-shaped curve between time and incidence of PPE/PE by calendar year (p-non-linear = 0.0017). The model confirms the nadir in the year 2013. DISCUSSION: We found a nonlinear temporal trend of PPE/PE incidence in children with a decrease from 2009 to 2013 and a subsequent increase until 2018. The former might be explained by a quasi elimination of serotype 1, the latter by an increase in the proportion of serotype 3 as demonstrated in German surveillance data of pediatric PPE/PE cases generated during the same observation period.
引用
- Sorg AL, Obermeier V, Liese JG, et al. Incidence trends of parapneumonic pleural effusions/empyema in children 2009 to 2018 from health insurance data: Only temporal reduction after the introduction of PCV13. Vaccine. 2021. PMID: 34006409. doi:10.1016/j.vaccine.2021.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。